Filing Flows › Ensysce Biosciences (ENSC) › Q2 2026 › vs Q1 2026
Ensysce Biosciences (ENSC) Q2 2026 vs Q1 2026 (quarter over quarter)
Ensysce Biosciences's revenue rose $203K (+21%) from $961K in Q1 2026 to $1.2M in Q2 2026.
Ensysce Biosciences, Q2 2026: revenue $1.2M (-15% year over year), operating margin -221.3%, net loss $2.6M, operating cash flow −$2.0M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $1.2M | $961K | $203K | +21% |
| Other income, net | $6K | $6K | −$301 | -5% |
| Net loss | $2.6M | $3.6M | −$986K | -28% |
| Costs & expenses | $3.7M | $4.5M | −$783K | -17% |
| Operating costs | $3.7M | $4.5M | −$783K | -17% |
| Research & development | $2.5M | $3.3M | −$875K | -26% |
| General & admin | $1.3M | $1.2M | $93K | +8% |
| Operating cash sources | $2.6M | $3.6M | −$986K | -28% |
| Depreciation | $7K | $7K | $0 | 0% |
| Share-based compensation | $2K | $9K | −$7K | -79% |
| Working capital & other | $600K | $40K | $560K | 15× |
| Cash used in operations | $2.0M | $3.5M | −$1.5M | -44% |
| Net loss absorbed | $2.6M | $3.6M | −$986K | -28% |
Questions
How much did Ensysce Biosciences's revenue grow quarter over quarter in Q2 2026?
Ensysce Biosciences's revenue rose $203K (+21%) from $961K in Q1 2026 to $1.2M in Q2 2026.